AAAAAA
Results:
1-7
|
Results: 7
Authors:
Royce, ME
Hoff, PM
Dumas, P
Lassere, Y
Lee, JJ
Coyle, J
Ducharme, MP
De Jager, R
Pazdur, R
Citation: Me. Royce et al., Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): A novelcamptothecin analog, J CL ONCOL, 19(5), 2001, pp. 1493-1500
Authors:
Wang, MLH
Yung, WKA
Royce, ME
Schomer, DF
Theriault, RL
Citation: Mlh. Wang et al., Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer, AM J CL ONC, 24(4), 2001, pp. 421-424
Authors:
Royce, ME
Hoff, PM
Pazdur, R
Citation: Me. Royce et al., Progress in colorectal cancer chemotherapy - How far have we come, how farto go?, DRUG AGING, 17(3), 2000, pp. 201-216
Authors:
Royce, ME
Medgyesy, D
Zukowski, TH
Dwivedy, S
Hoff, PM
Pazdur, R
Citation: Me. Royce et al., Colorectal cancer: Chemotherapy treatment overview, ONCOLOGY-NY, 14(12), 2000, pp. 40-46
Authors:
Royce, ME
McGarry, W
Bready, B
Dakhil, SR
Belt, RJ
Goodwin, JW
Gray, R
Hoff, PM
Winn, R
Pazdur, R
Citation: Me. Royce et al., Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer, J CL ONCOL, 17(10), 1999, pp. 3276-3282
Authors:
Pazdur, R
Royce, ME
Rodriguez, GI
Rinaldi, DA
Patt, YZ
Hoff, PM
Burris, HA
Citation: R. Pazdur et al., Phase trial of docetaxel for cholangiocarcinoma, AM J CL ONC, 22(1), 1999, pp. 78-81
Authors:
Brito, RA
Medgyesy, D
Zukowski, TH
Royce, ME
Ravandi-Kashani, F
Hoff, PM
Pazdur, R
Citation: Ra. Brito et al., Fluoropyrimidines: A critical evaluation, ONCOL-BASEL, 57, 1999, pp. 2-8
Risultati:
1-7
|